Conmed (CNMD) Tops Q1 EPS by 5c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CNMD Hot Sheet
Price: $53.23 +12.70%
Financial Fact:
Research and development expense: 8.35M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Research and development expense: 8.35M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Conmed (NYSE: CNMD) reported Q1 EPS of $0.79, $0.05 better than the analyst estimate of $0.74. Revenue for the quarter came in at $312.3 million versus the consensus estimate of $306.73 million.
GUIDANCE:
Conmed sees FY2024 EPS of $4.25-$4.35, versus the consensus of $4.33. Conmed sees FY2024 revenue of $1.33-1.355 billion, versus the consensus of $1.35 billion.
For earnings history and earnings-related data on Conmed (CNMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Marriott International (MAR) PT Lowered to $141 at Jefferies
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
